SI1613335T1 - Perivaskularno mezenhimsko prekurzorsko celično inducirano tvorjenje krvnih žil - Google Patents

Perivaskularno mezenhimsko prekurzorsko celično inducirano tvorjenje krvnih žil

Info

Publication number
SI1613335T1
SI1613335T1 SI200432157T SI200432157T SI1613335T1 SI 1613335 T1 SI1613335 T1 SI 1613335T1 SI 200432157 T SI200432157 T SI 200432157T SI 200432157 T SI200432157 T SI 200432157T SI 1613335 T1 SI1613335 T1 SI 1613335T1
Authority
SI
Slovenia
Prior art keywords
blood vessel
precursor cell
vessel formation
cell induced
mesenchymal precursor
Prior art date
Application number
SI200432157T
Other languages
English (en)
Inventor
Stan Gronthos
Andrew Zannettino
Original Assignee
Mesoblast, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31500707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1613335(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mesoblast, Inc. filed Critical Mesoblast, Inc.
Publication of SI1613335T1 publication Critical patent/SI1613335T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1392—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from mesenchymal stem cells from other natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200432157T 2003-03-28 2004-03-29 Perivaskularno mezenhimsko prekurzorsko celično inducirano tvorjenje krvnih žil SI1613335T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003901668A AU2003901668A0 (en) 2003-03-28 2003-03-28 Non-haemopoietic precursor cells
EP04723937.1A EP1613335B1 (en) 2003-03-28 2004-03-29 Perivascular mesenchymal precursor cell induced blood vessel formation
PCT/AU2004/000417 WO2004084921A1 (en) 2003-03-28 2004-03-29 Perivascular mesenchymal precursor cell induced blood vessel formation

Publications (1)

Publication Number Publication Date
SI1613335T1 true SI1613335T1 (sl) 2014-08-29

Family

ID=31500707

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200432157T SI1613335T1 (sl) 2003-03-28 2004-03-29 Perivaskularno mezenhimsko prekurzorsko celično inducirano tvorjenje krvnih žil

Country Status (14)

Country Link
US (6) US9169466B2 (sl)
EP (4) EP1613741A4 (sl)
JP (10) JP5721302B2 (sl)
CN (4) CN1809632B (sl)
AU (7) AU2003901668A0 (sl)
CA (4) CA2520273C (sl)
DK (1) DK1613335T3 (sl)
ES (3) ES2689483T3 (sl)
FR (1) FR20C1036I2 (sl)
NL (1) NL301059I2 (sl)
PL (1) PL1613335T3 (sl)
PT (1) PT1613335E (sl)
SI (1) SI1613335T1 (sl)
WO (2) WO2004084921A1 (sl)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US8062675B2 (en) 1999-07-07 2011-11-22 Angioblast Systems, Inc. Mesenchymal precursor cell
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US20050158289A1 (en) * 1999-07-07 2005-07-21 Simmons Paul J. Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals
US7670628B2 (en) * 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
DE602004028803D1 (de) * 2003-02-11 2010-10-07 John E Davies Vorläuferzellen aus der wharton sulze von humanen nabelschnüren
CA2581237C (en) * 2004-09-24 2018-11-06 Angioblast Systems, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc)
TR201900968T4 (tr) * 2004-09-24 2019-02-21 Mesoblast Inc Multipotansiyel genleşmiş mezenkimal prekürsör hücre soyu (memp) ve bunların kullanımı.
CN101155913B (zh) 2005-02-11 2011-07-06 新加坡科技研究局 增殖干细胞的方法
US8287853B2 (en) 2005-02-11 2012-10-16 Agency For Science, Technology And Research Methods of culturing mesenchymal stem cells
DK1869165T3 (en) 2005-04-12 2016-02-01 Mesoblast Inc Isolation of Adult Multipotent Cells by Tissue-Specific Alkaline Phosphate
WO2007019107A2 (en) * 2005-07-29 2007-02-15 University Of Virginia Patent Foundation Adipose tissue stem cells, perivascular cells and pericytes
EP1780265A1 (en) * 2005-10-25 2007-05-02 Stiftung CAESAR Differentiation of stem cells into chondrocytes
CA2634820C (en) 2005-12-22 2021-05-25 Jane Ennis Viable cells from frozen umbilical cord tissue
PL2029149T3 (pl) * 2006-05-05 2017-12-29 John E. Davies Uprzywilejowane immunologicznie i modulacyjne komórki progenitorowe
CN101516385B (zh) * 2006-07-12 2013-07-10 成血管细胞系统公司 过量新血管化的治疗
FR2909559B1 (fr) * 2006-12-06 2012-09-07 Inst Vaisseaux Et Du Sang Preparations cellulaires pour une utilisation comme agent stimulant la revascularisation
US20100040584A1 (en) * 2006-12-19 2010-02-18 Children's Medical Center Corporation Methods for promoting neovascularization
US20100158874A1 (en) * 2007-02-26 2010-06-24 Mount Sinai Hospital Compositions and Methods for Treating Peripheral Vascular Diseases
ES2923016T3 (es) 2007-08-06 2022-09-22 Mesoblast Inc Células precursoras mesenquimales TNAP+ para el tratamiento de enfermedades del tejido conectivo
JP5773366B2 (ja) 2008-04-21 2015-09-02 ティシュー リジェネレイション セラピューティックス、インコーポレイテッド 生物学的又は化学的作用物質に対する予防又はそれらの治療のために遺伝子改変されたヒト臍帯血管周囲細胞
KR101776959B1 (ko) 2008-06-25 2017-09-08 메소블라스트, 아이엔씨. 추간판의 치료 및/또는 재구성
CN102076844B (zh) * 2008-06-30 2013-08-07 成血管细胞系统公司 采用组合疗法的眼病和过度血管新生的治疗
WO2010011185A1 (en) * 2008-07-21 2010-01-28 Agency For Science, Technology And Research Stem cells obtained through in vitro culture with heparan sulfate
MX339624B (es) 2008-08-20 2016-06-02 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
MX2008014536A (es) * 2008-11-13 2009-01-16 Internac Para La Terapia Celul Compuesto de regeneracion celular.
KR101832497B1 (ko) 2008-11-20 2018-02-26 메소블라스트, 아이엔씨. 췌장 기능장애를 치료 또는 예방하는 방법
KR101764437B1 (ko) 2009-03-20 2017-08-02 메소블라스트, 아이엔씨. 재프로그램된 다분화능 세포의 생성 방법
WO2011022071A2 (en) 2009-08-20 2011-02-24 The Regents Of The University Of California Cardiac compositions
JP5810089B2 (ja) 2009-10-21 2015-11-11 マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ 体液ホメオスタシスのバイオマーカーとしてのｍｃａｍ
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
CA2803639C (en) 2010-07-02 2019-01-08 Mesoblast, Inc. Method of treating graft versus host disease
EP2606121B1 (en) * 2010-08-19 2016-05-11 The Regents of The University of California Compositions comrpising perivascular stem cells and nell-1 protein
CN101985052B (zh) * 2010-08-31 2013-11-06 中国人民解放军第二军医大学 自动捕获内皮祖细胞促进血管化的皮肤替代物及其构建方法
WO2012040408A2 (en) * 2010-09-23 2012-03-29 Children's Medical Center Corporation Engineered vascular adipose tissue
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
EP2709634B1 (en) * 2011-05-19 2020-09-09 Mesoblast, Inc. Methods for treating obesity and/or metabolic syndrome
KR102002090B1 (ko) * 2011-06-03 2019-07-19 메소블라스트, 아이엔씨. 신경성 질환을 치료 또는 예방하는 방법들
JP6265890B2 (ja) * 2011-06-03 2018-01-24 メゾブラスト，インコーポレーテッド 脳梗塞の影響を治療する方法
AU2012268078B2 (en) 2011-06-07 2017-06-01 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1
AU2012278925B2 (en) 2011-07-04 2016-05-19 Mesoblast, Inc. Methods of treating or preventing rheumatic disease
AU2012279995C1 (en) 2011-07-06 2019-10-24 Cell Therapy Limited Progenitor cells of mesodermal lineage
EP2734618B1 (en) * 2011-07-20 2017-06-14 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Pluripotent tendon and ligament perivascular cells
AU2012300221A1 (en) * 2011-08-29 2014-04-17 Safeguard Cell Technology Inc. Isolating and therapeutic use of perivascular medicinal cells
JP5831059B2 (ja) * 2011-09-07 2015-12-09 ソニー株式会社 光学的測定装置、フローサイトメーター及び光学的測定方法
US9177336B2 (en) * 2011-09-08 2015-11-03 Telefonaktiebolaget L M Ericsson (Publ) Apparatuses and methods for recommending a path through an information space
US9642878B2 (en) 2011-09-09 2017-05-09 Mesoblast, Inc. Methods for increasing osteoblastic function
CN102539736B (zh) * 2011-12-16 2015-04-29 北京汉氏联合生物技术有限公司 一种cd106阳性细胞、其鉴定、制备方法及应用
WO2014022376A2 (en) 2012-08-01 2014-02-06 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
CN104684561A (zh) * 2012-08-01 2015-06-03 联合治疗公司 利用间充质干细胞的肺动脉高血压的治疗
CA2893951C (en) 2012-12-12 2022-05-03 Mesoblast, Inc. Methods of treating or preventing respiratory conditions
JP6572130B2 (ja) * 2012-12-12 2019-09-04 メソブラスト、インコーポレイテッド 内皮機能不全及び炎症の疾患の治療
EP3415150B1 (en) 2013-01-09 2021-08-18 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
AU2014296259B2 (en) 2013-07-30 2017-04-27 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
JP6612227B2 (ja) 2013-11-16 2019-11-27 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
JP2017500316A (ja) * 2013-12-13 2017-01-05 メソブラスト インターナショナル エスエイアールエル ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復する方法
EP3122866B1 (en) 2014-03-25 2019-11-20 Terumo BCT, Inc. Passive replacement of media
WO2015155187A1 (en) * 2014-04-07 2015-10-15 Mesoblast International Sarl Improved stem cell composition
CA2944703C (en) 2014-04-11 2023-09-19 The Administrators Of The Tulane Educational Fund Cell-surface marker of early msc aging
WO2015189063A1 (en) 2014-06-10 2015-12-17 Mesoblast International Sàrl Treatment of immune disorders
EP3168297B1 (en) * 2014-07-11 2020-09-16 Metcela Inc. Cardiac cell culture material
JP6830059B2 (ja) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド スケジュール化された細胞フィーディング
CA2971514A1 (en) 2014-12-23 2016-06-30 Mesoblast International Sarl Prevention of progressive heart failure
SG10202008024VA (en) 2014-12-23 2020-10-29 Mesoblast Int Sarl Method for Treating Heart Failure
WO2016139340A1 (en) 2015-03-04 2016-09-09 Mesoblast International Sàrl Cell culture method for mesenchymal stem cells
JP6797833B2 (ja) 2015-05-05 2020-12-09 メゾブラスト・インターナショナル・エスアーエールエル 効力検定
CA3177726A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
CN106119189B (zh) * 2016-07-11 2020-04-10 山东亚大药业有限公司 胎儿有核红细胞的分离纯化方法及试剂盒
WO2018080990A1 (en) 2016-10-24 2018-05-03 United Therapeutics Corporation Enhancement of msc immunomodulatory properties by treprostinil
JP7105195B2 (ja) 2016-11-15 2022-07-22 株式会社カネカ 胎児付属物に由来する間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
KR102407387B1 (ko) * 2017-02-24 2022-06-10 가부시키가이샤 메토세라 섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법
CN110612344B (zh) 2017-03-31 2023-09-12 泰尔茂比司特公司 细胞扩增
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3619294A1 (en) 2017-05-04 2020-03-11 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
AU2018372631A1 (en) 2017-11-22 2020-05-21 Mesoblast International Sarl Cellular compositions and methods of treatment I
US20200368291A1 (en) 2017-12-28 2020-11-26 Kaneka Corporation Cell population including adhesive stem cells, production method therefor and pharmaceutical composition
AU2019370723A1 (en) 2018-10-31 2021-05-13 Mesoblast International Sarl Expansion of hematopoietic stem cells
CN109321522A (zh) * 2018-11-20 2019-02-12 潍坊市康华生物技术有限公司 一种制备牙髓干细胞的方法
BR112021013158A2 (pt) 2019-01-02 2021-09-14 Mesoblast International Sàrl Método para tratar a dor lombar
CN113573720A (zh) 2019-01-03 2021-10-29 迈索布拉斯特国际有限公司 提高视力的方法
US20220160776A1 (en) 2019-01-28 2022-05-26 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
AU2020277691A1 (en) 2019-05-23 2021-12-23 Mesoblast International Sarl Functional recovery from cerebral infarction
US20220233600A1 (en) 2019-06-14 2022-07-28 Kaneka Corporation Cell population comprising mesenchymal cells, pharmaceutical composition comprising the same, and method for producing the same
AU2020325825A1 (en) 2019-08-05 2022-03-17 Mesoblast International Sarl Cellular compositions comprising viral vectors and methods of treatment
US20230293590A1 (en) 2020-08-10 2023-09-21 Mesoblast International Sárl Cellular compositions and methods of treatment
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
WO2023238074A1 (en) 2022-06-08 2023-12-14 Mesoblast International Sarl Mesenchymal progenitor cells for enhancing partial reprogramming of target cells
CN115184246B (zh) * 2022-09-14 2023-07-04 天津昂赛细胞基因工程有限公司 一种利用cd155评价间充质干细胞生物学效力的方法
WO2024121820A1 (en) 2022-12-09 2024-06-13 Mesoblast International Sarl Pre-licensed composition and cell culture methods
WO2024121818A1 (en) 2022-12-09 2024-06-13 Mesoblast International Sarl Method of treating heart failure in subjects with persistent inflammation
WO2024121821A1 (en) 2022-12-09 2024-06-13 Mesoblast International Sarl Conditioned media and use of the same

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5811094A (en) * 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5226914A (en) * 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
IL107642A0 (en) 1992-11-20 1994-02-27 Amgen Inc Progenitor b cell stimulating factor
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5405722A (en) * 1993-12-22 1995-04-11 Rca Thomson Licensing Corp. Method for combined baking-out and sealing of an electrophotographically processed screen assembly for a cathode-ray tube
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
AU1119397A (en) 1995-11-14 1997-06-05 Regents Of The University Of Minnesota Ex vivo culture of stem cells
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US5980887A (en) 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
CA2294944A1 (en) 1997-07-03 1999-01-14 Osiris Therapeutics, Inc. Human mesenchymal stem cells from peripheral blood
EP1007631B2 (en) 1997-07-14 2009-02-18 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
AU9127098A (en) 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
DK1082410T3 (da) 1998-05-29 2007-11-26 Osiris Therapeutics Inc Humane CD45 - og/eller fibroblast mesenchymale stamceller
EP1100870B1 (en) 1998-07-31 2008-01-02 Genzyme Corporation Improvement of cardiac function by mesenchymal stem cell transplantation
EP1165830B1 (en) * 1999-03-10 2017-07-12 University of Pittsburgh of the Commonwealth System of Higher Education Adipose-derived stem cells and lattices
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) * 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US7670628B2 (en) 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
US8062675B2 (en) * 1999-07-07 2011-11-22 Angioblast Systems, Inc. Mesenchymal precursor cell
US20050158289A1 (en) 1999-07-07 2005-07-21 Simmons Paul J. Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals
AU6298400A (en) 1999-07-26 2001-02-13 Chemetall Plc Metal surface treatment
DK1226233T3 (da) 1999-08-05 2011-10-03 Abt Holding Co Multipotente voksne stamceller og fremgangsmåder til isolering heraf
CA2346362C (en) 2000-05-26 2010-06-15 Stemcell Technologies Inc. Novel antibody compositions for preparing enriched mesenchymal progenitor preparations
ES2423898T3 (es) * 2000-07-21 2013-09-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Citoblastos de pulpa dental de seres humanos adultos in vitro e in vivo
EP1367899A4 (en) 2001-02-14 2004-07-28 Leo T Furcht TOTIPOTENT ADULT STEM CELLS, SOURCES OF SUCH CELLS, METHODS FOR OBTAINING AND MAINTAINING SAME, METHODS FOR DIFFERENTIATING THESE CELLS, METHODS OF USING SAME, AND CELLS DERIVED FROM THE ABOVE-MENTIONED CELLS
FR2827868A1 (fr) 2001-07-30 2003-01-31 Bp Chem Int Ltd Procede et dispositif de fabrication en continu d'un polymere d'alcoylene aromatique
AUPR703601A0 (en) 2001-08-15 2001-09-06 Peter Maccallum Cancer Institute, The Identification and isolation of somatic stem cells and uses thereof
JP2003052365A (ja) * 2001-08-20 2003-02-25 Japan Science & Technology Corp 哺乳動物からの間葉系幹細胞の分離及びその利用方法
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
JP4061487B2 (ja) * 2002-11-21 2008-03-19 始 大串 血管新生を目的とする移植材料及びその製造方法
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
ATE511753T1 (de) * 2003-04-19 2011-06-15 Us Gov Health & Human Serv Postnatale stammzellen und deren verwendungen
TR201900968T4 (tr) 2004-09-24 2019-02-21 Mesoblast Inc Multipotansiyel genleşmiş mezenkimal prekürsör hücre soyu (memp) ve bunların kullanımı.
CA2581237C (en) 2004-09-24 2018-11-06 Angioblast Systems, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc)
GB0812683D0 (en) * 2008-07-11 2008-08-20 Chalabi Rifat A Multi-heat zone gasifier
US7942266B2 (en) * 2009-04-01 2011-05-17 Lincoln Global, Inc. Electrode packaging to reduce handling damage

Also Published As

Publication number Publication date
EP1613335A1 (en) 2006-01-11
NL301059I1 (nl) 2020-08-12
ES2465226T3 (es) 2014-06-05
JP2006521096A (ja) 2006-09-21
PT1613335E (pt) 2014-05-19
FR20C1036I2 (fr) 2022-11-18
CN1809632A (zh) 2006-07-26
CA2520390A1 (en) 2004-10-07
JP2017148076A (ja) 2017-08-31
EP2380971B1 (en) 2020-02-12
JP2019006814A (ja) 2019-01-17
US9175267B2 (en) 2015-11-03
JP5721302B2 (ja) 2015-05-20
US20060286077A1 (en) 2006-12-21
CN1822846B (zh) 2013-03-20
US9169466B2 (en) 2015-10-27
CN103202857A (zh) 2013-07-17
EP2380971A2 (en) 2011-10-26
AU2004223798A1 (en) 2004-10-07
JP6188435B2 (ja) 2017-08-30
WO2004084921A1 (en) 2004-10-07
AU2004223798B2 (en) 2006-06-15
US20160317581A1 (en) 2016-11-03
EP1613335B1 (en) 2014-02-12
US20120082649A1 (en) 2012-04-05
JP6096232B2 (ja) 2017-03-15
CN1822846A (zh) 2006-08-23
US10421946B2 (en) 2019-09-24
AU2009227897B2 (en) 2011-09-15
JP2017014285A (ja) 2017-01-19
JP6096082B2 (ja) 2017-03-15
JP2013256515A (ja) 2013-12-26
ES2689483T3 (es) 2018-11-14
US20150368614A1 (en) 2015-12-24
EP1613741A4 (en) 2007-07-04
EP2380969B1 (en) 2018-07-04
ES2784378T3 (es) 2020-09-24
AU2009227881A1 (en) 2009-11-12
AU2004224830B2 (en) 2006-06-29
US20060193840A1 (en) 2006-08-31
CN103224907A (zh) 2013-07-31
JP2013208130A (ja) 2013-10-10
JP2015156874A (ja) 2015-09-03
EP1613335A4 (en) 2007-07-04
FR20C1036I1 (fr) 2020-02-10
US20070065938A1 (en) 2007-03-22
US20170204373A9 (en) 2017-07-20
EP2380971A3 (en) 2012-01-25
AU2006203628A1 (en) 2006-09-07
AU2003901668A0 (en) 2003-05-01
CA2816489A1 (en) 2004-10-07
AU2004224830A1 (en) 2004-10-07
AU2009227881B2 (en) 2011-08-25
US7947266B2 (en) 2011-05-24
CA2872395A1 (en) 2004-10-07
EP1613741A1 (en) 2006-01-11
EP2380969A3 (en) 2011-11-09
DK1613335T3 (da) 2014-05-19
JP2015110659A (ja) 2015-06-18
PL1613335T3 (pl) 2014-09-30
JP6043469B2 (ja) 2016-12-14
AU2006203627A1 (en) 2006-09-07
EP2380969A2 (en) 2011-10-26
CN1809632B (zh) 2013-06-05
WO2004085630A1 (en) 2004-10-07
AU2009227897A1 (en) 2009-11-12
CA2520390C (en) 2015-03-24
JP6257559B2 (ja) 2018-01-10
CA2520273C (en) 2015-06-02
JP2006521121A (ja) 2006-09-21
CA2520273A1 (en) 2004-10-07
NL301059I2 (nl) 2021-09-16
CA2816489C (en) 2022-08-23
CN103224907B (zh) 2015-05-06
JP2011072315A (ja) 2011-04-14

Similar Documents

Publication Publication Date Title
PT1613335E (pt) Formação de vasos sanguíneos induzida por células precursoras mesenquimais perivasculares
IL172988A0 (en) Bioreactor
GB0410118D0 (en) Novel bioreactor
HK1098534A1 (en) Disposable reaction vessel with integrated optical elements
GB2388563B (en) Bio cell cleaning centrifuge having bio cell cleaning rotor provided with cleaning liquid distributor
EP1687491A4 (en) W.C. A RESERVOIR COMPRISING AN AUTOMATIC WATER HUNTING
GB0420881D0 (en) Bioreactor
GB0318411D0 (en) Vessel
GB0416424D0 (en) Vessels
AU2003300043A8 (en) Carriers attached to blood cells
GB2408702B (en) Bioreactor
GB0428338D0 (en) Fluid-containment vessel
GB0422532D0 (en) Drinking vessel
GB0411829D0 (en) Drinking vessel
TW592199U (en) Vessel with improved structure
TW557929U (en) Improved structure of liquid-tight antiexplosive distiller for wine making
TW586515U (en) Improved structure for container steeped with boiled water
AU2002351100A1 (en) Porous vessel bioreactor
AU2004904721A0 (en) Improved Drinking Vessel
AU2004904502A0 (en) Improved Submersible Vessel
AU2004906964A0 (en) Improved Submersible Vessel
IL160333A0 (en) Drinking vessel
AU2004907393A0 (en) Electro-chemical reactor
GB0311377D0 (en) Drinking vessel
GB0312042D0 (en) Bioreactor